Hematology

BMT survivors face a higher risk of skin cancer, with age, graft-vs-host disease, and treatment influencing outcomes.

ICI treatment before transplant enhances survival in relapsed Hodgkin lymphoma, though it increases the risk of acute GVHD.

Detectable antibodies reduce COVID-19 risk in immunosuppressed individuals, emphasizing the need for tailored protection strategies.

The NHS has approved exa-cel, a revolutionary gene-editing therapy for sickle cell disease, offering hope for a cure.

Shared care after HCT improves quality of life at day 100 without affecting survival, offering a viable post-transplant model.

New research identifies VLCFA metabolism as a target to boost multiple myeloma treatment efficacy and combat drug resistance.

A recent study has uncovered key insights into the differing tumour rejection behaviours of chimeric antigen receptor T cells (CAR-T) targeting CD19…

Low lymphocyte count at diagnosis and during treatment is associated with poorer survival in multiple myeloma patients.